Abstract
Metastatic breast cancer remains largely incurable, and the mechanisms underlying the transition from primary to metastatic breast cancer remain elusive. We analyzed the complex landscape of primary and metastatic breast cancer using scRNA-seq data from twenty-three female patients with either primary or metastatic disease to elucidate the genetic and molecular mechanisms underlying changes in the metastatic tumor ecosystem. We identify specific subtypes of stromal and immune cells critical to forming a pro-tumor microenvironment in metastatic lesions, including CCL2+ macrophages, cytotoxic T cells with an exhausted gene signature, and FOXP3+ regulatory T cells. Analysis of cell-cell communication highlights a marked decrease in tumor-immune cell interactions in metastatic tissues, likely strengthening the immunosuppressive microenvironment. In contrast, primary breast cancer samples displayed increased activation of the TNF-α signaling pathway via NF-kB, indicating a potential therapeutic target. Our study comprehensively characterizes the transcriptional landscape encompassing primary and metastatic breast cancer.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Oregon Health & Science University (OHSU) Institutional Review Board (IRB). All biospecimens were collected and analyzed under the OHSU IRB-approved CEDAR (IRB #20750) or MMTERT observational study (Mitri 2018) (IRB #16113). Participant eligibility was determined by the enrolling physician, and informed written consent was obtained from all subjects. All biopsy biospecimen used in this study were prospectively collected freshly for single-cell RNA sequencing library construction. Raw single-cell RNA sequencing data for this study are available in the NCBI BioProject database under accession number PRJNA1140267. Processed single-cell RNA sequencing data and single-cell RNA seq objects can be found as follows: https://doi.org/10.5281/zenodo.13743373
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Raw single-cell RNA sequencing data for this study are available in the NCBI BioProject database under accession number PRJNA1140267. Processed single-cell RNA sequencing data and single-cell RNA seq objects can be found as follows: https://doi.org/10.5281/zenodo.13743373
